linjc16/ctgov huggingface dataset:
The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Breast Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine findings of positron emission tomography and diffusion weighted magnetic resonance in primary lesion and axillary metastasis of breast cancer and compare of two imaging modality in these patients.

Detailed Description
-----------------
We aimed that to correlate both primary lesion 18F-fluorodeoxyglucose (FDG) maximum standardized uptake value (SUVmax) and diffusion-weighted imaging (DWI) apparent diffusion coefficient (ADC) with clinicopathological prognostic factors and compare the prognostic value of these indexes in breast cancer in this study. The evaluated and compared parameters are SUVmax and ADC according to age, tumour size, lymph node metastasis, receptor status, histologic grade, modified Nottingham prognostic index.

Official Title
-----------------
The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Detection of Primary Tumor and Axillary Metastasis for Breast Cancer: SUVMax Against to ADC

Conditions
-----------------
Breast Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Newly diagnosis of breast cancer for which surgical intervention is planned Exclusion Criteria: patients received neoadjuvant chemotherapy before breast surgery
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Histologic grade<br>According to the modified criteria of Bloom and Richardson grading system: grade 1, 2 and 3 | |
| Axillary metastasis<br>Group A: axillary lymph node metastasis Group B: no axillary lymphatic metastasis | |
| Modified Nottingham prognostic index<br>NPI = pathological tumour size (cm) × 0.2 + lymph node stage (1, 2 or 3) + histological grade (1, 2 or 3) The cut-off points of the index were 3.4 and 5.4 to divide patients into the good (≤3.4), moderate (3.41-5.4) and poor (>5.4) prognostic groups | |
| Oestrogen receptor status<br>Negative Positive | |
| Progesterone receptor status<br>Negative Positive | |
| HER-2 neu status<br>Negative Positive | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the relationships between both SUVmax and ADC and clinicopathological prognostic factors |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast Neoplasms, Positron-Emission Tomography, Diffusion Magnetic Resonance Imaging
A Novel System to Detect Falls in Real-life Conditions

Study Overview
=================
Brief Summary
-----------------
Medical alert devices with automatic fall detection functionality use accelerometry to detect a fall and can signal for help if the wearer forgets to, or is incapable of, pressing the alert button. This can save lives and prevent complications associated with long periods of time spent on the floor after a fall. In this project, the sensitivity and false alarm rate of a commercially available medical alert device will be tested in a population of 200 community-dwelling older adults.

Conditions
-----------------
Falls

Intervention / Treatment
-----------------
* Other: Fall Detection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Enrolled in the STRIDE Study at the Boston trial site (http://www.stride-study.org/). Exclusion Criteria: Uses a medical alert device

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Primary<br>Older adult study participants will be recruited from the cohort of participants in the STRIDE Study at the Boston trial site (http://www.stride-study.org/). | Other: Fall Detection<br>* All participants will wear a device configured to detect falls.<br>* Other names: ActivePERS;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The sensitivity and specificity of ActivePERS fall detection algorithms will be measured by comparing the occurence of falls detected by the wearable device to study participant self reported falls |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Near falls as measured by patient self report |  | 2 years |
Effect Of Laparoscopic Sleeve Gastrectomy on Vitamin D, Parathormone and Calcium Levels

Study Overview
=================
Brief Summary
-----------------
Obesity is likely to be the disease of the 21th century. The growth of obesity is worldwide, a pandemic, and has increased globally in the last 30 years. Developed countries were more affected, but developing countries have increasingly contributed to this epidemic as they continue to modernize. The national and global burden of obesity, with its public health and financial implications, is projected to increase markedly in the next two decades. the study aimed to assess the effect of Vit D supplementation on preventing altered levels of calcium, Vit D, and parathormone after laparoscopic sleeve gastrectomy.

Official Title
-----------------
Effect Of Laparoscopic Sleeve Gastrectomy (LSG) on Vitamin D, Parathormone and Calcium Levels

Conditions
-----------------
Bariatric Surgery Candidate, Obesity, Morbid, Vitamin D Deficiency, Calcium Deficiency

Intervention / Treatment
-----------------
* Procedure: Laparoscopic sleeve gastrectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult male or female from 18 to 60 ages BMI: 40 kg/m2 or > 35 kg/m2 comorbidities e.g., hypertension and DM conservative management for obesity failed in at least 2 years Exclusion Criteria: BMI > 60 history of bariatric surgery symptomatic reflux oesophagitis stomach cancer active peptic ulcer disease alcohol or drug abuse major psychological disturbance major eating troubles risky anesthesia risky surgery.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Laparoscopic sleeve gastrectomy<br>After sleeve gastrectomy, assessment of vitamin D, calcium and parathormone levels is performed. | Procedure: Laparoscopic sleeve gastrectomy<br>* Laparoscopic resection of a part of the stomach to enable the patient to lose weight.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vitamin D level assessment | Assessment of the vitamin D level after sleeve gastrectomy. | 1 year |
To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fed and Fasted Conditions

Study Overview
=================
Brief Summary
-----------------
To demonstrate the relative bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride capsules (Pulvules) in healthy adult males under fed and fasted conditions.

Official Title
-----------------
Comparative, Randomized, Single-Dose, 3-way Crossover Bioavailability Study of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Health Adult Males Under Fed and Fasted Conditions Following Administration of a 40 mg Dose

Conditions
-----------------
Depression

Intervention / Treatment
-----------------
* Drug: Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)
* Drug: Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.)
* Drug: Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: Positive test results for HIV or hepatitis B or C. Treatment for drug or alcohol dependence.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.) | Drug: Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)<br> <br> |
| Experimental: 2<br>Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.) | Drug: Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.)<br> <br> |
| Active Comparator: 3<br>Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista) | Drug: Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bioequivalence based on AUC and Cmax |  | 141 days |
Effects of Dietary Nitrate on Age-related Vascular Function

Study Overview
=================
Brief Summary
-----------------
Purpose of the study is to characterize the chronic effect of dietary nitrate on vascular function in healthy volunteers with particular emphasis on age-related alterations.

Official Title
-----------------
Effects of Dietary Nitrate Supplementation on Age-related Vascular Dysfunction

Conditions
-----------------
Endothelial Dysfunction

Intervention / Treatment
-----------------
* Dietary Supplement: Nitrate
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >55 Years Healthy Exclusion Criteria: known cardiovascular disease

Ages Eligible for Study
-----------------
Minimum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Nitrate<br>150µmol /Kg bodyweight /day | Dietary Supplement: Nitrate<br>* Dietary Supplement<br>|
| Placebo Comparator: PLacebo<br>150µmol /Kg bodyweight /day | Dietary Supplement: Placebo<br>* Dietary Supplement<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endothelial function measured by flow-mediated dilation (FMD) | The effect of dietary nitrate on endothelial function as measured by flow-mediated dilation (FMD) after forearm ischemia and reperfusion. | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
age related Endothelial Dysfunction
Prevention of Adhesions Following Flexor Tendon Injury Within Zone II With Vascularized Finger Dorsal Fascial Flap

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to report a new method of flexor tendon repair in zone II with combined standard modified Kessler technique and vascularized finger dorsal fascial flap pedicled with dorsal cutaneous branch of proper digital artery ,which is transported to finger volar for placement of a mechanical barrier between flexor digitorum superficialis /profundus tendons. The function outcomes of 14 patients (Group A) with flexor tendon repair in zone II with this new technique were compared with those of 32 patients (Group B) with flexor tendon repair in zone II with standard modified Kessler technique. This new technique may prevent serious adhesions between flexor digitorum superficialis /profundus tendons.

Conditions
-----------------
Restoration of the Sliding Function Effectively After Flexor Tendon Repair Within Zone II

Intervention / Treatment
-----------------
* Procedure: vascularized finger dorsal fascial flap


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients requiring flexor tendon repair or reconstruction within zoneⅡ Exclusion Criteria:
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| dorsal fascial flap<br>combined with standard modified Kessler technique and vascularized finger dorsal fascial flap pedicled with dorsal cutaneous branch of proper digital artery ,which is transported to finger palmar for placement of a mechanical barrier between flexor digitorum superficialis /profundus tendons. | Procedure: vascularized finger dorsal fascial flap<br> <br> |
| standard modified Kessler technique<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the modified Strickland system |  | 3 12 months | 
| degrees of the maximum active flexion at the distal interphalangeal joint |  | 3 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tendon repair
Peritoneal Irrigation at Elective Cesarean Section

Study Overview
=================
Brief Summary
-----------------
All participants will be randomized at elective cesarean section to either irrigation with 500 to 1000 ml of warm normal saline after closure of visceral peritoneum or non irrigation

Detailed Description
-----------------
All participants will be randomized at elective cesarean section to either irrigation with 500 to 1000 ml of warm normal saline after closure of visceral peritoneum or non irrigation during the procedure of elective lower segment cesarean section

Official Title
-----------------
Comparative Study Between Intraabdominal Irrigation and Non Irrigation During Elective Cesarean Section

Conditions
-----------------
Postoperative Recovery

Intervention / Treatment
-----------------
* Procedure: Elective Cesarean Section
* Other: Peritoneal irrigation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Singleton pregnancy Gestational age 36 - 40 weeks Elective Cesarean section Under spinal anaesthesia Exclusion Criteria: Chronic diseases as Diabetes and hypertension Intestinal diseases as Crohn's disease Psychological and neurological conditions affecting pain sensation women with ferbrile morbidity before the operation The need for general anesthesia

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Peritoneal irrigation<br>Irrigation with 500 - 1000 ml of warm normal saline will be done after closure of visceral peritoneum | Procedure: Elective Cesarean Section<br>* lower segment cesarean section<br>* Other names: CS;Other: Peritoneal irrigation<br>* Irrigation of peritoneal cavity with 500 - 1000 ml of warm normal saline<br>|
| Active Comparator: Non peritoneal irrigation<br>No Irrigation with 500 - 1000 ml of warm normal saline will be done after closure of visceral peritoneum | Procedure: Elective Cesarean Section<br>* lower segment cesarean section<br>* Other names: CS;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intestinal recovery | Auscultation of intestinal sounds | 24 hours after operation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Temperature | measuring the oral temperature by thermometer | every hour for 16 hours after the operation | 
| postoperative pain | Pain score felt by the patient using Visual analogue score | 24 hours after surgery |
Role of Inflammation in Progressive Multifocal Leukoencephalopathy (PML)

Study Overview
=================
Brief Summary
-----------------
This is a continuation of our previous studies on Progressive Multifocal Leukoencephalopathy (PML). We will focus on the role of inflammation in PML, and define prognostic markers of disease evolution.

Detailed Description
-----------------
To determine precisely what are the host or viral factors that may predict a favorable outcome for PML patients and the role of inflammation in preventing JCV from causing brain disease. One of the goals of this study is to help establish non-invasive markers of PML evolution by studying the brain metabolism in PML lesions using Magnetic Resonance Imaging (MRI), Magnetic Spectroscopy (MRS) and other advanced imaging modalities.

Official Title
-----------------
Role of Inflammation in PML

Conditions
-----------------
Progressive Multifocal Leukoencephalopathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PML patients of 18 years of age or older will be included in this study. Exclusion Criteria: Presence of opportunistic brain lesions other than PML. ( e.g., toxoplasmosis, lymphoma) Presence of confounding neurological disorder such as brain neoplasm etc. In addition patients with a contraindication to MRI examination will be excluded from study. Contraindications to the MRI examination include: Medically unstable or hematological, renal, or hepatic dysfunction. Cardiac pacemaker Internal clips, Metal implants, or external clips with 10 mm of the head. Metal in the eyes. Pregnant Claustrophobia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PML<br>These are subjects who have confirmed PML. | |
| Control<br>These are subjects who do not have PML. They may be healthy or immune compromised due to Cancer, Transplant, or HIV. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
JC Virus
Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH

Study Overview
=================
Brief Summary
-----------------
Our primary objective is to compare two treatment options for prevention of seizures following a subarachnoid hemorrhage and determine if a short-course regimen of levetiracetam is as efficacious in the prevention of in-hospital seizures when compared to an extended course.

Detailed Description
-----------------
This is a prospective, single-center, randomized, controlled trial. Patients admitted with spontaneous SAH (and meet enrollment criteria) will be randomized to either levetiracetam 1000 mg twice daily for 3 days or levetiracetam 1000mg twice daily until hospital discharge.

Official Title
-----------------
Comparison of Short Duration Levetiracetam to Extended Course Levetiracetam for Seizure Prophylaxis Following Subarachnoid Hemorrhage

Conditions
-----------------
Subarachnoid Hemorrhage

Intervention / Treatment
-----------------
* Other: Brief LEV
* Other: Extended LEV


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >18 years of age Diagnosis of spontaneous SAH Exclusion Criteria: SAH secondary to trauma or arteriovenous malformation Early death (defined as death within 3 days of presentation) Known allergy to levetiracetam Know seizure history on chronic AEDs Pregnancy Current incarceration

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Brief LEV<br>Administration of three days of levetiracetam twice daily after SAH | Other: Brief LEV<br>* Levetiracetam 1000mg BID x 3 days for prophylaxis<br>|
| Other: Extended LEV<br>Administration of levetiracetam twice daily after SAH | Other: Extended LEV<br>* Levetiracetam 1000mg BID for length of hospital stay for prophylaxis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In-hospital Seizures | from admission to In-hospital seizures after aSAH | from hospital admission to hospital discharge | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Subarachnoid Hemorrhage, Seizure Prophylaxis, Levetiracetam